Rhodococcus equi is a facultative, intracellular, gram-positive coccobacillus increasingly reported as an opportunistic pathogen in human immunodeficiency virus-positive patients. However, the optimal drug regimen for treating R. equi pulmonary or systemic infections is not yet known. Therefore, a model of intravenously infected nude mice with disseminated infection was created to study the efficacy of antibiotics alone or in combination as determined by the reduction of bacterial CPU per gram in the lungs and spleen after 4 and 11 days of treatment. The studied antibiotics possessing low MICs against R. equi strains were amikacin, ciprofloxacin, erythromycin, imipenem, minocycline, rifampin, and vancomycin. Vancomycin, imipenem, and rifampin were the most effective agents in monotherapy. On the other hand, amikacin, ciprofloxacin, erythromycin, and minocycline alone were not active in this model. The most active drug combinations were those including vancomycin. No antibiotic-resistant mutants were selected in vivo with treatment involving any drugs used alone or in combination. Although the treatment recommended until now for R. equi infections is rifamnpin plus erythromycin, this study suggests that antibiotic combinations which include vancomycin may be the most effective in vivo.
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Rhodotoccus equi is a gram-positive coccobacillus which is well known by veterinary microbiologists because it causes pneumonia in foals (24) . In humans, pneumonia and lung abscesses are the most frequent infections due to this facultative intracellular organism (8, 12, 14) . However, nonpulmoniary infections such as endophthalmitis, osteomyelitis, and brain, kidney, and pelvis abscesses are also reported (5, 10, 11, 14, 23, 27, 29) . All except two described cases of R. equi infection have been in immunocompromised patients (14) . Since the AIDS epidemic, R. equi infections are increasiigly reported (8, 14, 26) . On the basis of the results of treatment of R. equi pneumonia in foals, rifampin combined with erythromycin is known to be effective in vivo (15) .
However, in humans, the optimal antimicrobial regimen is not yet known, since frequent relapses occur during the course of the disease, especially in AIDS cases (8) . Therefore, the aim of this work was to assess the abilities of several antibiotics and antibiotic combinations to clear an R. equi inoculum in experimentally infected mice. Since R. equi infections are of a chronic mode in immunocompromised humans, intravenously (i.v.) infected nude mice in which R. equi persisted in the lungs and spleen for at least 3 weeks were used as the experimental model of infection. The idea to use such an animal model was provided by the results of testing the antibacterial activities of in Listeria monocytogenes-infected nude mice and by the persistence of R. equi in infected normal mice treated with cyclophosphamide (16, 17, 19) . The choice of antibiotics was guided by the results of previous susceptibility studies in vitro (2, 4, 22, 30) . The following seven compounds were studied because they possessed relatively low MICs: amikacin, ciprofloxacin, erythromycin, imipenem, minocycline, rifampin, and vancomycin. Therapeutic trials with these drugs in monotherapy as well as in combination were performed. Seven combinations of antibiotics were studied. Four of them were studied because they were synergistic according to previous in vitro determinations of fractional inhibitory concentration indices (22) , namely, imipenem plus amikacin, erythromycin plus minocycline, rifampin plus erythromycin, and rifampin plus minocycline. The efficacy of the combination imipenem plus vancomycin was studied because imipenem combined with glycopeptides has been shown recently to have successfully treated two cases of human R. equi infection (la, 25). The combination ciprofloxacin plus rifampin was studied because both of these antibiotics possess high intramacrophagic uptake (28) and are known to treat several other intracellular infections. The last drug combination, rifampin plus vancomycin, was studied because both rifampin and vancomycin alone were particularly active in a preliminary in vivo therapeutic trial. Finally, since in vivo selection of antibiotic-resistant mutants in patients under treatment has been described previously (2, 12, 21) , selection of such mutants in mice treated with antibiotics alone or in combination were also evaluated.
MATERIALS AND METHODS Drugs used. The antimicrobial agents used in this study were obtained from laboratory standard powders and were used immediately after being diluted. The agents and their sources were amikacin (Bristol), vancomycin (Eli Lilly), erythromycin lactobionate (Abbott), imipenem/cilastatin at a fixed ratio of 1:1 (Merck Sharp & Dohme), ciprofloxacin (Bayer), rifampin (Gruppo Lepetit), and minocycline (Lederle). All of the antibiotics were dissolved in sterile distilled water at the appropriate dilutions before being used.
Challenge organism. The strain R. equi PN 1002, which had been simultaneously isolated from sputum and blood cultures of a human immunodeficiency virus-positive patient who died of pneumonia, was used (20 Administration of drugs. Therapeutic trials with nude mice were initiated 4 days after the animals were inoculated in order to let the infection peak in both the lungs and spleen.
Adjustments were made in the dosing schedule and in the dosages of the antibiotics to account for mouse pharmacokinetics in an effort to parallel the pharmacokinetics of these agents in humans. The original antibiotic solutions were appropriately diluted in sterile water to obtain the requisite dose, which was injected subcutaneously in a volume of 0.1 to 0.2 ml for each mouse. Rifampin (10 mg/kg of body weight) was given once a day, and minocycline (15 mg/kg) was given twice a day. Erythromycin (50 mg/kg), imipenemcilastatin (60 mg of each per kg), amikacin (20 mg/kg), vancomycin (25 mg/kg), and ciprofloxacin (20 mg/kg) were given every 6 h. Therapeutic trials were performed with these antibiotics alone and with the following seven antibiotic combinations: amikacin plus imipenem-cilastatin, erythromycin plus minocycline, rifampin plus erythromycin, rifampin plus minocycline, rifampin plus ciprofloxacin, rifampin plus vancomycin, and vancomycin plus imipenemcilastatin. The total number of animals in each group of treated mice was six. All mice except the controls were treated daily from day 4 to day 15 after i.v. inoculation.
Controls consisted of infected but untreated animals.
Levels of agents in serum. Pooled sera were obtained from groups of three noninfected Swiss mice, sacrificed at 0.25, 0.50, 1, 2, 4, or 8 h after a single subcutaneous dose of the antibiotic. Animals were briefly anesthetized with ether and exsanguinated by intracardiac puncture. Blood samples were centrifuged, and serum was collected. Serum concentrations of ciprofloxacin, erythromycin, imipenem, minocycline, and rifampin were determined by an agar well diffusion method of bioassay (6) . The indicator strains were Eschenchia coli ATCC 25922 for determination of ciprofloxacin and imipenem levels in serum and Staphylococcus aureus ATCC 25923 for determination of minocycline, erythromycin, and rifampin levels in serum. Concentrations in serum of amikacin and vancomycin were measured by using the fluorescence polarization immunoassay developed by Abbott Laboratories, North Chicago, Ill. (1) . Pharmacokinetic analyses were performed by routine graphical methods, and parameters were evaluated by standard methods (13) . Cmax was the maximal concentration observed, Tmax was the time to Cmax, t112 was the elimination half-life calculated by using linear least-squares regression, and the inhibitor quotient (IQ) was calculated as follows: IQ = Cmax/MIC (7) . The MICs retained for the IQ calculations were those of the R. equi strain used in the experimental infections.
Quantities of R. equi in lungs and spleen. In the experiment which established the comparison between clearance of R. equi CFU counts from the lungs and spleen in Swiss mice and that in nude Swiss mice, a group of three mice was sacrificed on days 2, 4, 8, 15 , and 21 after the infectious i.v. challenge. For therapeutic trials, three mice in each group were sacrificed on days 8 and 15 after the infectious challenge. Day 8 was chosen because it represented a short (4-day) therapy, and day 15 permitted an evaluation of the effectiveness of treatment for a longer period. In all experiments, lungs and spleen were removed aseptically, weighed, and placed in 2 ml of sterile buffered water. Organs were homogenized with a hand-held glass homogenizer, and serial 10-fold dilutions were plated on Trypticase soy agar. After 48 h of incubation at 30°C (the temperature for R. equi optimal growth [24] ), colonies were of sufficient size to be counted, and the number of bacterial CFU per gram of tissue was determined. Titers were expressed as log1o CFU per gram of organ. The titers for the infected mice were compared with those for the control mice, and the difference was In vivo selection of antibiotic-resistant mutants. The in vivo emergence of mutants that were resistant to the drug with which the mice were treated was determined by inoculating nondiluted tissue extract at each time of sacrifice on Trypticase soy agar impregnated with antibiotics. The antibiotic concentrations (in micrograms per milliliter) in the plates, which were 10-fold higher than the MICs, were as follows: amikacin, 10; ciprofloxacin, 2.5; erythromycin, 0.25; imipenem, 2.5; minocycline, 1.2; rifampin, 0.6; vancomycin, 1.2.
Statistics. Standard randomization procedures were employed in selecting animals to be killed at scheduled intervals. CFU counts of each treated group were compared with those of the control group and with those of each of the other groups by variance analysis. This was performed on the basis of the results of the parametric Tukey's studentized range test (SAS/stat; SAS Institute Inc., Cary, N.C. 1989) for a fixed value of P = 0.05.
RESULTS
Pharmacokinetic data. Following a single subcutaneous dose of each antibiotic in Swiss mice, pharmacokinetic data were obtained ( equi. The kinetics of clearance of bacterial counts from lungs and spleen in both groups of mice over a 3-week period are given in Fig. 1 . In both groups of mice, bacterial counts were greater in the spleen than in the lungs and peaked at day 4 postinoculation. However, the kinetics of CFU counts over time followed the same trend in lungs and spleen. In immunocompetent mice, the bacterial CFU counts progressively decreased in lungs and spleen over 3 weeks and reached the limits of detectability (i.e., 1.0 log1o CFU) within 21 days. On the other hand, in nude mice, the bacterial CFU counts remained the same for a given organ from day 4 to day 21 x 107 to 6 x 107 CFU of R. equi was high, no mice died during the 3-week experiment. Therapeutic trials. Treatment of nude mice began on day 4 after the inoculum challenge and was continued daily until day 15. A comparison of the mean variation (+ standard deviation) in bacterial log1o CFU counts in the lungs and spleen of treated mice and control mice at day 8 and day 15 after the infectious challenge are given in Fig. 2 . A similar trend in decrease of bacterial CFU counts was obtained for a given drug regimen in the lungs and spleen from day 8 to day 15. The following treatments did not lead to a statistically significant decrease in bacterial CFU compared with that of the controls in either the lungs or spleen at day 8 and day 15: amikacin, erythromycin, ciprofloxacin, minocycline, and erythromycin combined with minocycline. For the other treatments, the antibacterial effect was more marked at day 15 than at day 4. Vancomycin monotherapy led to a statistically significant difference in reducing the bacterial CFU compared with any other monotherapy. At day 15, vancomycin monotherapy lead to a greater decrease in bacterial CFU than did rifampin combined with erythromycin. However, vancomycin combined with another drug was not statistically different from vancomycin monotherapy. Among therapeutic regimens including drugs in combination, the most effective were those including vancomycin. Moreover, only two antibiotic combinations led to a statistically significant greater decrease in CFU counts than was observed with the relevant antibiotic alone: rifampin combined with minocycline and rifampin combined with erythromycin as compared with rifampin alone.
Selection of antibiotic-resistant mutants in vivo. The frequencies of selection of antibiotic-resistant mutants in the spleen after drug monotherapy were as follows: amikacin, 6 X 10-4; imipenem, 9 x 10-6; ciprofloxacin, <1 x 1 erythromycin, <1 x 10-7; minocycline, <1 x 10-7; rifampin, 1 x 10-7; vancomycin, <1 x 10-7. For a given antibiotic, frequencies of selection of antibiotic-resistant mutants were identical when the mice were treated with the drug alone or in combination. In the lungs, the frequencies of selection of antibiotic-resistant mutants were not detectable, since there was a lower number of bacterial CFU counts than in the spleen. The same frequencies of selection of antibiotic-resistant mutants were obtained with the untreated control. Therefore, no selection of antibiotic-resistant mutants occurred in vivo. The antibiotic-resistant mutants obtained resulted from selection in vitro rather than selection in vivo. showed a surprising lack of activity against R. equi-infected animals. On the other hand, therapy with vancomycin or imipenem, which are antibiotics not known to concentrate in macrophages, led to a significant reduction in the CFU counts in the lungs and spleen after 4 or 11 days of treatment. Furthermore, monotherapy efficacy may be more related to the serum IQ than to the known intracellular uptake of the antibiotics. The efficacy of vancomycin was noteworthy and may be related to its high IQ, 296, as well as to its bactericidal properties against R. equi. Therefore, one may suggest that extramacrophagic development is of significant importance in the growth in vivo of R. equi, as it is known to be for L. monocytogenes (3). Moreover, as suggested for L. monocytogenes, the inefficacy in vivo of minocycline and erythromycin despite their low MICs may have resulted from their inactivation due to the effect of a low pH in the phagolysosomes where R. equi may persist (16, 24) . (iii) The low therapeutic effect of ciprofloxacin for R. equi infections may be due to its low antibacterial effect. R. equi is much less susceptible in vitro to ciprofloxacin than gram-negative bacteria are. This lack of ciprofloxacin efficacy may explain the previous selection of a rifampin-resistant strain from a patient treated with ciprofloxacin plus rifampin resulting, in fact, in a rifampin monotherapy (21) . (iv) Our results confirm the efficacy of the rifampin-erythromycin combination, as indicated by the results of treatment of infected foals (15 [9] ) with which R. equi may be combined in AIDS cases (14) .
DISCUSSION

